BioSpace News Archive

According to Nova one advisor, the global Congestive Heart Failure Drugs market size is expected to hit around USD 20.33 billion by 2030 from valued at USD 6.25 billion in 2021 and growing at a CAGR of 14.70% from 2022 to 2030.

According to Nova one advisor, the global Gastrointestinal Diagnostics market size was valued at USD 5.59 billion in 2022 and is predicted to hit USD 7.9 billion by 2030 with a registered CAGR of 4.88% during the forecast period 2022 to 2030.

Latest Study on “Next-Generation Sequencing Data Analysis Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.

The grant is matched by in-kind support bringing approximately AUD$2.2 million in funding for BiVACOR’s clinical advancement.

MorphoSys AG announced that preliminary results from the ongoing Phase 1/2 study of tulmimetostat monotherapy in heavily pretreated patients with advanced cancers showed responses or disease stabilization in five cohorts with evaluable patients.

Solid Biosciences Inc., a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, announced that it will implement a 1-for-15 reverse split of its common stock.

IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 third quarter financial results before the market opens on Thursday, November 3 rd . IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.

Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO) today announced that results from the Waldenstrom macroglobulinemia (“WM”) cohort and other interim data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy being conducted at Fred Hutchinson Cancer Center (“Fred Hutch”), will be presented at the 11th International Workshop for Waldenstrom’s Macroglobulinemia (“IWWM-11”) taking place in Madrid, Spain.

Integer Holdings Corporation, a leading medical device outsource manufacturer, announced results for the three months ended September 30, 2022.

Delphi Diagnostics, Inc and Quantum Leap Healthcare Collaborative™ (QLHC) announce the inclusion of Delphi’s SET2,3™ test for use in the I-SPY 2 TRIAL for patients with locally advanced breast cancer.